CB-103 is under clinical development by Cellestia Biotech and currently in Phase II for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CB-103 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CB-103 is under development for the treatment of notch dependent solid tumors including T-cell acute lymphoblastic leukemia, graft versus host disease. The drug candidate is administered through oral route and it is formulated as capsules. It acts by targeting the Notch intracellular domain.
It was under development for the treatment of rhabdomyosarcoma, fibrosarcoma, liposarcoma, cholangiocarcinoma, HER 2 negative breast cancer.
It was under development for the treatment of Metastatic Colorectal Cancer, Gastric Cancer, Metastatic Ovarian Cancer , Cervical Cancer, Non-Small Cell Lung Cancer, Metastatic Melanoma , Osteosarcoma , Adenoid Cystic Carcinoma (ACC), Glioblastoma Multiforme (GBM), Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Marginal Zone B-cell Lymphoma , Splenic Marginal Zone B-Cell Lymphoma, Mantle Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL), Peripheral T-Cell Lymphomas (PTCL), CNS Lymphoma,Triple-Negative Breast Cancer (TNBC) and Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Cellestia Biotech overview
Cellestia Biotech (Cellestia) is a biopharmaceutical company that develops anti-cancer drugs for the treatment of oncology and immunological disorders. The company’s lead compound includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. Its CB-103 blocks the notch pathway and inhibits cancerous cells in breast, lung, blood, or any other tissue of the body. Cellestia Biotech’s products finds application in the treatment of NOTCH dependent leukemia, lymphoma and solid tumors. The company conducts research and development activities in the field of oncology and cancer stem cells biology. It operates through its research laboratory located in Lausanne. Cellestia Biotech is headquartered in Basel, Switzerland.
For a complete picture of CB-103’s drug-specific PTSR and LoA scores, buy the report here.